Brentuximab Vedotin: A CD30-Directed ADC (Antibody Drug conjugate)

Jan 13, 2022

40 likes | 50 Views

Brentuximab vedotin is a CD30-directed ADC (Antibody Drug conjugate); meaning that it consists of a targeted therapy monoclonal antibody and an antineoplastic agent. These act together in order to destroy cancer cells. The brentuximab vedotin is licensed to treat patients with relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T-cell NHL (non-Hodgkin lymphoma).

amitsharma2020

Download Presentation

Brentuximab Vedotin: A CD30-Directed ADC (Antibody Drug conjugate)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

ADCETRIS® (brentuximab Vedotin)
Commom Adcertris Side Effects 1. Low blood counts . 2. Peripheral neuropathy (numbness and 3.tingling of the hands and feet) 4.Fatigue (feeling tired or weak) 5.Nausea. 6.Diarrhea. 7.Fever.
Small text